{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Investigational medicinal product will be stored per the Pharmacy Manual and refrigerated at', 'approximately 5=3\u00b0C. Deviations from the recommended storage conditions should be reported', 'to the Sponsor and use of the IMP halted until authorization for its continued use has been', 'provided by the Sponsor or designee, as described in the Pharmacy Manual.', 'A Sponsor representative or designee will be permitted, upon request, to audit the supplies,', 'storage, dispensing procedures, and records.', 'Instructions specific to unused IMP and additional storage details are provided in the Pharmacy', 'Manual.', '6.2.5.', 'Packaging and Labeling', 'All packaging, labeling, and production of IMP will be in compliance with current Good', 'Manufacturing Practices, or local applicable regulations, where necessary. Investigational', 'medicinal product labels and external packaging will include all appropriate information as per', 'local labeling requirements. Additional details will be available in the Pharmacy Manual.', '6.2.6.', 'Accountability', 'The Investigator or designee will maintain accurate records of receipt and the condition of the', 'IMP supplied for this study, including dates of receipt. In addition, accurate records will be kept', 'of when and how much IMP is dispensed and administered to each patient in the study. Any', 'reasons for departure from the protocol dispensing regimen must also be recorded.', 'At the completion of the study, there will be a final reconciliation of all IMP.', 'Further instructions about drug accountability are detailed in the Pharmacy Manual.', 'Any quality issue noticed with the receipt or use of an IMP (deficiency in condition, appearance,', 'pertaining documentation, labeling, expiration date, etc) must be promptly notified to the', 'Sponsor. Some deficiencies may be recorded through a complaint procedure (see', 'Section 7.5.6.8).', 'A potential defect in the quality of IMP may be subject to initiation of a recall procedure by the', 'Sponsor. In this case, the Investigator will be responsible for promptly addressing any request', 'made by the Sponsor, in order to recall the IMP and eliminate potential hazards.', 'Under no circumstances will the Investigator supply IMP to a third party (except for duties and', 'taxes paid [DTP] shipment, for which a courier company has been approved by the Sponsor),', 'allow the IMP to be used other than as directed by this clinical trial protocol, or dispose of IMP', 'in any other manner.', '6.3.', 'Concomitant Medications', \"Use of concomitant medications will be recorded on the patient's eCRF as specified in the\", 'Schedule of Assessments (Table 1). This includes all prescription medications, herbal', 'preparations, over the counter medications, vitamins, and minerals. Any changes in medications', 'during the study will also be recorded on the eCRF.', 'Local standard treatment of hemophilia is considered to be, but not limited to, IV infusion of', \"aPCC or rFVIIa. Use of these agents will be captured in the patient's eDiary.\", 'Property of the Sanofi Group - strictly confidential', '45']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Use of prothrombin complex concentrates for bleeding episode management is not permitted.', 'Antifibrinolytics may be used as single agents, but may not be used in combination with factor or', 'BPA. Use of FEIBA and rFVIIa as combination therapy is not recommended.', '6.3.1.', 'Management of Bleeding Episodes', 'The occurrence of bleeding episodes is a typical characteristic of hemophilia; [2, 7, 8] bleeding', 'episodes will be recorded as efficacy assessments of fitusiran and will not be considered as AEs', 'unless the criteria for SAEs are met (see AEs definitions in Section 7.5.6.1). Bleeding episodes', 'will be recorded in the eDiary. For bleeding episodes in which there was no BPA infusion or', 'other type of intervention employed, the reason the bleeding episodes were untreated will be', 'recorded in the eDiary (see Section 7.2.1).', 'Investigators will establish and provide instructions for an individualized bleed management plan', 'based on the guidelines in Table 4 for each patient.', 'The bleed management plan should be reviewed by the Investigator or designee with the patient', 'at each clinic visit (and contact every 2 weeks between clinic visits) and updated as necessary.', 'Doses of FVIII and FIX are included for completeness. It is expected that these inhibitor', 'patients will be routinely managed with aPCC or rFVIIa.', '6.3.1.1.', 'Bleeding Episode Management Recommendations for Patients in the On-', 'Demand Treatment Arm (Patients Not Receiving Fitusiran)', 'For patients not receiving fitusiran (on-demand arm), bleeding management therapy with BPAs', 'will be managed based on the local standard practice for treating hemophilia patients with', 'inhibitors, as routinely administered by the physician. Where clinical circumstances allow, it is', 'recommended that the patient contact the Investigator for all events that may be suspected to be', 'or are characteristic of a bleeding episode. If adequate hemostasis does not occur after two doses', 'of BPA, the patient should contact the site for further instruction. If the patient feels the need to', \"administer doses higher than the patient's bleeding episode management plan recommends, or at\", 'a higher frequency, it is recommended that the patient contact the site. See Section 7.2.1', 'regarding patient use of the eDiary and site alerts that will assist in this process.', '6.3.1.2.', 'Bleeding Episode Management Recommendations for Patients in the Fitusiran', 'Treatment Arm', 'Given the mechanism of action and pharmacodynamics profile of fitusiran, the BPA dose', 'necessary to safely and effectively treat breakthrough bleeding episodes in patients receiving', 'fitusiran (fitusiran treatment arm) will be lower than standardly prescribed. This is supported by', 'data from the Phase 1 study in which bleed events were managed with factor or BPA, as well as', 'additional modeling and ex vivo spiking data. More detailed information on the clinical', 'experience in bleeding episode management in Phase 1 and Phase 1/2 fitusiran studies, as well as', \"supportive nonclinical studies is provided in the Investigator's Brochure.\", 'After administration of fitusiran, AT lowering will be progressing toward therapeutic levels. As', 'quickly as 7 days after the initial fitusiran dose, the majority of patients will have AT levels at or', 'below 60% residual activity. By 14 days after dosing, it is expected that 94% of patients will', 'have AT lowering of \">50%, with a median value of 66.8%. Based on these AT kinetics, it is', 'Property of the Sanofi Group - strictly confidential', '46']\n\n###\n\n", "completion": "END"}